Sakthimala Jagadeesan: Developing Therapeutics for Intestinal Disorder Pain
Sakthimala: Our mission is to develop first-in-class oral small molecule therapeutics for treating barrier dysfunction diseases. Compromises in the epithelial barrier can lead to intestinal disorders, including inflammatory bowel disease (IBD). At Artus Therapeutics, Inc., we strongly believe our therapeutic approach for treating barrier dysfunction will address highly unmet needs, not just in IBD, but for other types of barrier dysfunctional diseases as well.